Pharmacological outcomes in juvenile myoclonic epilepsy: Support for sodium valproate
- 1 January 2016
- journal article
- Published by Elsevier in Epilepsy Research
- Vol. 119, 62-66
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Prognosis of juvenile myoclonic epilepsy 45 years after onsetNeurology, 2013
- Epidemiology of juvenile myoclonic epilepsyEpilepsy & Behavior, 2013
- Management of juvenile myoclonic epilepsyEpilepsy & Behavior, 2013
- Consensus on diagnosis and management of JME: From founder's observations to current trendsEpilepsy & Behavior, 2013
- Treating myoclonic epilepsy in children: state-of-the-art.Expert Opinion on Pharmacotherapy, 2013
- Road to refractory epilepsy: The Glasgow storyEpilepsia, 2013
- Predictors for long‐term seizure outcome in juvenile myoclonic epilepsy: 25–63 years of follow‐upEpilepsia, 2012
- The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trialThe Lancet, 2007
- Epidemiology of Idiopathic Generalized EpilepsiesEpilepsia, 2005
- Evidence‐based Treatment of Idiopathic Generalized Epilepsies with Older Antiepileptic DrugsEpilepsia, 2005